Comparing Pioglitazone and Rosiglitazone Effects on Lipids
Author Information
Author(s): Mark A. Deeg, Tan Meng H.
Primary Institution: Lilly Research Laboratories, Eli Lilly & Co.
Hypothesis
How do pioglitazone and rosiglitazone compare in their effects on lipid metabolism in patients with type 2 diabetes?
Conclusion
Pioglitazone has a more favorable impact on serum lipids compared to rosiglitazone.
Supporting Evidence
- Pioglitazone reduced fasting triglycerides by 12%, while rosiglitazone increased them by 15%.
- Both medications raised LDL cholesterol, but the increase was significantly greater with rosiglitazone.
- Pioglitazone increased HDL cholesterol by 14.9%, compared to 7.8% with rosiglitazone.
Takeaway
This study looks at two medications for diabetes and finds that one, pioglitazone, is better at improving fat levels in the blood than the other, rosiglitazone.
Methodology
The study reviewed randomized clinical trials comparing the lipid effects of pioglitazone and rosiglitazone.
Limitations
The review does not include studies on troglitazone, which has been removed from the market.
Participant Demographics
Patients with type 2 diabetes and dyslipidemia.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website